Product image of Lacopat (Lacosamide) supplied by GNH India

Lacopat

Active Ingredient:
Lacosamide
Origin:
EU

Lacopat (Lacosamide)

Lacosamide, the active ingredient in Lacopat, is a sodium channel blocker presented as an oral formulation for oral use. It is employed as adjunctive therapy for partial‑onset seizures in epilepsy and for primary generalized tonic‑clonic seizures in patients requiring additional seizure control.

GNH India supplies Lacopat as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Customers benefit from comprehensive documentation, batch traceability, and responsive technical support.

Manufacturer / TM Owner

G.L. Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lacosamide is used as an adjunctive anticonvulsant in the management of seizure disorders.

  • Partial‑onset seizures: reduces seizure frequency when added to existing antiepileptic therapy.
  • Primary generalized tonic‑clonic seizures: provides additional seizure control as adjunctive treatment.
  • Epilepsy (overall): contributes to overall seizure management in patients with refractory epilepsy.

How It Works

  • Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing hyperexcitable neuronal membranes, it reduces repetitive neuronal firing that underlies seizure activity. This selective modulation of sodium channel kinetics distinguishes it from agents that block fast inactivation, providing a complementary mechanism when combined with other antiepileptic drugs. The effect is dose‑dependent and contributes to overall seizure threshold elevation.

Side Effects

Lacosamide may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Dizziness: sensation of light‑headedness or unsteadiness.
  • Nausea: mild gastrointestinal upset.
  • Headache: transient cranial discomfort.
  • Fatigue: feeling of tiredness or reduced energy.
  • Vision changes: blurred or double vision.
  • Tremor: involuntary shaking of limbs.

Serious or Rare Side Effects

  • Cardiac arrhythmia: abnormal heart rhythm, including PR interval prolongation.
  • Atrioventricular block: impaired conduction between atria and ventricles.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Suicidal thoughts: emergence of depressive ideation or suicidal behavior.

Precautions & Warnings

When prescribing lacosamide, clinicians should consider several safety and handling precautions.

  • Renal impairment: adjust dose in patients with reduced kidney function.
  • Hepatic dysfunction: monitor liver enzymes and consider dose modification.
  • Cardiac conduction: evaluate ECG for PR interval prolongation before initiating therapy.
  • Concomitant antiepileptics: assess for additive CNS depression.
  • Pregnancy and lactation: use only if potential benefit outweighs risk, as data are limited.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and keep in original packaging.

Avoid Interactions

Lacosamide can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inducers: may reduce lacosamide plasma levels, decreasing effectiveness.
  • Concomitant use with other sodium channel blockers: increased risk of cardiac conduction abnormalities.

Moderate Interactions (Monitor Closely)

  • CYP2C19 inhibitors: may raise lacosamide concentrations, requiring monitoring.
  • Anticoagulants (e.g., warfarin): potential for altered bleeding risk.
  • Other antiepileptic drugs: may require dose adjustments based on therapeutic response.

Frequently Asked Questions

Lacopat contains the active ingredient lacosamide, which is prescribed as an adjunctive therapy for patients with partial‑onset seizures and for those with primary generalized tonic‑clonic seizures who need additional seizure control alongside other antiepileptic medicines.

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neurons, stabilising hyper‑excitable membranes and reducing the repetitive firing that leads to seizure activity. This mechanism complements other antiepileptic agents that act on different phases of sodium channel function.

The specific dose of Lacopat is determined by the prescribing clinician based on the individual’s clinical condition, age, renal and hepatic function, and response to therapy. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for lacosamide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To order Lacopat, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacopat (lacosamide) belongs to the sodium channel blocker class and offers a unique mechanism by enhancing slow inactivation of sodium channels. Compared with other agents that block fast inactivation, lacosamide may provide additive seizure control when used in combination, especially in patients who have not achieved adequate control with other therapies.

Lacopat should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and avoid exposure to direct sunlight or extreme temperatures to maintain its stability and potency.

Lacopat is administered orally, typically as tablets or capsules, and should be taken with or without food as directed by the prescribing clinician. The exact route and timing are individualized, and patients should follow the instructions given by their healthcare provider.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, atrioventricular block, and rare severe skin reactions like Stevens‑Johnson syndrome. Patients should be monitored for any signs of cardiac issues or severe dermatologic reactions, and immediate medical attention is required if such events occur.

Lacopat is contraindicated in patients with known hypersensitivity to lacosamide or any component of the formulation. Caution is advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking interacting medications that could markedly increase lacosamide levels.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lacosamide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT